https://www.selleckchem.com/GSK-3.html
29, 95% credible interval [CrI] 1.22 to 4.25), 200 mg/day (RR=4.35, 95%CrI 2.31 to 8.01) and 300 mg/day (RR=6.02, 95%CrI 3.22 to 11.1) involved a higher risk of gastrointestinal AEs. Similarly, tramadol 100-300 mg/day showed a higher risk of CNS AEs and withdrawals. However, the risk of cardiovascular AEs remained unclear. Only tramadol 300mg/day showed minimal improvement in pain and function but with increasing AEs compared with placebo. Tramadol may not be sufficiently recommended for knee or hip OA by presented evidence, especially in patients
Curtir
Comentario
Compartilhar
